Literature DB >> 24563256

Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection.

Keer Sun1, Dennis W Metzger.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a leading contributor to mortality during recent influenza pandemics. The mechanism for this influenza-induced susceptibility to secondary S. aureus infection is poorly understood. In this study, we show that innate antibacterial immunity was significantly suppressed during the recovery stage of influenza infection, even though MRSA superinfection had no significant effect on viral burdens. Compared with mice infected with bacteria alone, postinfluenza MRSA-infected mice exhibited impaired bacterial clearance, which was not due to defective phagocyte recruitment, but rather coincided with reduced intracellular reactive oxygen species levels in alveolar macrophages and neutrophils. NADPH oxidase is responsible for reactive oxygen species production during phagocytic bacterial killing, a process also known as oxidative burst. We found that gp91(phox)-containing NADPH oxidase activity in macrophages and neutrophils was essential for optimal bacterial clearance during respiratory MRSA infections. In contrast to wild-type animals, gp91(phox-/-) mice exhibited similar defects in MRSA clearance before and after influenza infection. Using gp91(phox+/-) mosaic mice, we further demonstrate that influenza infection inhibits a cell-intrinsic contribution of NADPH oxidase to phagocyte bactericidal activity. Taken together, our results establish that influenza infection suppresses NADPH oxidase-dependent bacterial clearance and leads to susceptibility to secondary MRSA infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24563256      PMCID: PMC3965630          DOI: 10.4049/jimmunol.1303049

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice.

Authors:  Anupa Kudva; Erich V Scheller; Keven M Robinson; Chris R Crowe; Sun Mi Choi; Samantha R Slight; Shabaana A Khader; Patricia J Dubin; Richard I Enelow; Jay K Kolls; John F Alcorn
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

2.  Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia.

Authors:  K Z Vardakas; D K Matthaiou; M E Falagas
Journal:  Eur Respir J       Date:  2009-06-18       Impact factor: 16.671

3.  Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections.

Authors:  Keer Sun; Jianqiang Ye; Daniel R Perez; Dennis W Metzger
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

4.  Bone marrow chimeras and c-fms conditional ablation (Mafia) mice reveal an essential role for resident myeloid cells in lipopolysaccharide/TLR4-induced corneal inflammation.

Authors:  Holly R Chinnery; Eric C Carlson; Yan Sun; Michelle Lin; Sandra H Burnett; Victor L Perez; Paul G McMenamin; Eric Pearlman
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

5.  Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung.

Authors:  Cherrie-Lee Small; Christopher R Shaler; Sarah McCormick; Mangalakumari Jeyanathan; Daniela Damjanovic; Earl G Brown; Petra Arck; Manel Jordana; Charu Kaushic; Ali A Ashkar; Zhou Xing
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

6.  Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection.

Authors:  Lyn Finelli; Anthony Fiore; Rosaline Dhara; Lynnette Brammer; David K Shay; Laurie Kamimoto; Alicia Fry; Jeffrey Hageman; Rachel Gorwitz; Joseph Bresee; Timothy Uyeki
Journal:  Pediatrics       Date:  2008-10       Impact factor: 7.124

7.  Neutrophil depletion causes a fatal defect in murine pulmonary Staphylococcus aureus clearance.

Authors:  Charles M Robertson; Erin E Perrone; Kevin W McConnell; W Michael Dunne; Barrett Boody; Tejal Brahmbhatt; M Julia Diacovo; Nico Van Rooijen; Lisa A Hogue; Carolyn L Cannon; Timothy G Buchman; Richard S Hotchkiss; Craig M Coopersmith
Journal:  J Surg Res       Date:  2008-03-13       Impact factor: 2.192

8.  Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice.

Authors:  Arash Shahangian; Edward K Chow; Xiaoli Tian; Jason R Kang; Amir Ghaffari; Su Y Liu; John A Belperio; Genhong Cheng; Jane C Deng
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

9.  A postinfluenza model of Staphylococcus aureus pneumonia.

Authors:  Mei-Ho Lee; Carlos Arrecubieta; Francis J Martin; Alice Prince; Alain C Borczuk; Franklin D Lowy
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

10.  Community-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection.

Authors:  Ronan J Murray; James O Robinson; Jodi N White; Frank Hughes; Geoffrey W Coombs; Julie C Pearson; Hui-Leen Tan; Glenys Chidlow; Simon Williams; Keryn J Christiansen; David W Smith
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more
  52 in total

1.  Influenza Suppresses Neutrophil Recruitment to the Lung and Exacerbates Secondary Invasive Pulmonary Aspergillosis.

Authors:  Joshua M Tobin; Kara L Nickolich; Krishnaveni Ramanan; Matthew J Pilewski; Kristina D Lamens; John F Alcorn; Keven M Robinson
Journal:  J Immunol       Date:  2020-06-10       Impact factor: 5.422

Review 2.  The immunology of influenza virus-associated bacterial pneumonia.

Authors:  Keven M Robinson; Jay K Kolls; John F Alcorn
Journal:  Curr Opin Immunol       Date:  2015-02-24       Impact factor: 7.486

3.  Immunomodulators targeting MARCO expression improve resistance to postinfluenza bacterial pneumonia.

Authors:  Muzo Wu; John G Gibbons; Glen M DeLoid; Alice S Bedugnis; Rajesh K Thimmulappa; Shyam Biswal; Lester Kobzik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-04-13       Impact factor: 5.464

4.  Resistance to Acute Macrophage Killing Promotes Airway Fitness of Prevalent Community-Acquired Staphylococcus aureus Strains.

Authors:  Vijaya Kumar Yajjala; Vinai Chittezham Thomas; Christopher Bauer; Tyler D Scherr; Karl J Fischer; Paul D Fey; Kenneth W Bayles; Tammy Kielian; Keer Sun
Journal:  J Immunol       Date:  2016-04-06       Impact factor: 5.422

5.  Monocytes Represent One Source of Bacterial Shielding from Antibiotics following Influenza Virus Infection.

Authors:  Karl J Fischer; Vijaya Kumar Yajjala; Shruti Bansal; Christopher Bauer; Ruiling Chen; Keer Sun
Journal:  J Immunol       Date:  2019-02-11       Impact factor: 5.422

Review 6.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

Review 7.  The role of viral, host, and secondary bacterial factors in influenza pathogenesis.

Authors:  John C Kash; Jeffery K Taubenberger
Journal:  Am J Pathol       Date:  2015-03-05       Impact factor: 4.307

8.  Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.

Authors:  Dennis W Metzger; Yoichi Furuya; Sharon L Salmon; Sean Roberts; Keer Sun
Journal:  J Infect Dis       Date:  2015-02-03       Impact factor: 5.226

Review 9.  Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease.

Authors:  Agnieszka Rynda-Apple; Keven M Robinson; John F Alcorn
Journal:  Infect Immun       Date:  2015-07-27       Impact factor: 3.441

10.  Effects of Influenza on Alveolar Macrophage Viability Are Dependent on Mouse Genetic Strain.

Authors:  Danielle Califano; Yoichi Furuya; Dennis W Metzger
Journal:  J Immunol       Date:  2018-05-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.